137 related articles for article (PubMed ID: 31718346)
1. 20 years of rituximab treatment: what have we learnt?
Renner C
Future Oncol; 2019 Dec; 15(36):4119-4121. PubMed ID: 31718346
[No Abstract] [Full Text] [Related]
2. Rituximab biosimilars for B-cell lymphomas: a decade of real-world experience from India.
Nair R; Radhakrishnan VS; Mallath MK
Lancet Haematol; 2021 Aug; 8(8):e548-e549. PubMed ID: 34329574
[No Abstract] [Full Text] [Related]
3. A Phase II Trial of Rituximab Combined With Pegfilgrastim in Patients With Indolent B-cell Non-Hodgkin Lymphoma.
Torka P; Patel P; Tan W; Wilding G; Bhat SA; Czuczman MS; Lee KP; Deeb G; Neppalli V; Mavis C; Wallace P; Hernandez-Ilizaliturri FJ
Clin Lymphoma Myeloma Leuk; 2018 Jan; 18(1):e51-e60. PubMed ID: 29233743
[TBL] [Abstract][Full Text] [Related]
4. Tumour cell surface antigen targeted therapies in B-cell lymphomas: Beyond rituximab.
Ku M; Chong G; Hawkes EA
Blood Rev; 2017 Jan; 31(1):23-35. PubMed ID: 27568879
[TBL] [Abstract][Full Text] [Related]
5. Increased proportion of CD20+ T cells after rituximab treatment in patient with neuromyelitis optica later diagnosed with lung B-cell lymphoma: A case report.
Lee JK; Kwon S; Han JH; Yoon SE; Kim BJ; Kang ES
J Neuroimmunol; 2021 Jun; 355():577564. PubMed ID: 33862419
[TBL] [Abstract][Full Text] [Related]
6. Rituximab in B-Cell Hematologic Malignancies: A Review of 20 Years of Clinical Experience.
Salles G; Barrett M; Foà R; Maurer J; O'Brien S; Valente N; Wenger M; Maloney DG
Adv Ther; 2017 Oct; 34(10):2232-2273. PubMed ID: 28983798
[TBL] [Abstract][Full Text] [Related]
7. Long-term outcome of diffuse large B-cell lymphoma: Impact of biosimilar rituximab and radiation.
Ganesan P; Sagar TG; Kannan K; Radhakrishnan V; Rajaraman S; John A; Sundersingh S; Mahajan V; Ganesan TS
Indian J Cancer; 2017; 54(2):430-435. PubMed ID: 29469072
[TBL] [Abstract][Full Text] [Related]
8. Outcomes of adults with relapsed or refractory Burkitt and high-grade B-cell leukemia/lymphoma.
Short NJ; Kantarjian HM; Ko H; Khoury JD; Ravandi F; Thomas DA; Garcia-Manero G; Khouri M; Cortes JE; Wierda WG; Verstovsek S; Estrov Z; Ferrajoli A; Thompson PA; Pierce S; O'Brien SM; Jabbour E
Am J Hematol; 2017 Jun; 92(6):E114-E117. PubMed ID: 28295472
[No Abstract] [Full Text] [Related]
9. New treatment for non-Hodgkin B-cell lymphomas with a special focus on the impact of junctional adhesion molecules.
Imhof BA; Matthes T
Swiss Med Wkly; 2017; 147():w14487. PubMed ID: 28944932
[TBL] [Abstract][Full Text] [Related]
10. The use of ofatumumab in the treatment of B-cell malignancies.
Soe ZN; Allsup D
Future Oncol; 2017 Dec; 13(29):2611-2628. PubMed ID: 28850252
[TBL] [Abstract][Full Text] [Related]
11. Outcomes of patients with relapsed low-grade lymphoma retreated with rituximab are similar to rituximab naïve patients.
Vijenthira A; Maganti M; Kukreti V; Kuruvilla J; Tiedemann R; Chen C; Crump M; Prica A
Leuk Lymphoma; 2019 Oct; 60(10):2576-2579. PubMed ID: 30997853
[No Abstract] [Full Text] [Related]
12. Can rituximab unlock the innate potential of checkpoint blockade in the CNS?
Rubenstein JL
Leuk Lymphoma; 2019 Feb; 60(2):281-283. PubMed ID: 30188237
[No Abstract] [Full Text] [Related]
13. Rituximab biosimilars in hematologic malignancies: the need for a real-world approach.
Nava-Parada P; Shelbaya A; Nabhan C
Future Oncol; 2020 Sep; 16(26):2017-2027. PubMed ID: 32598173
[TBL] [Abstract][Full Text] [Related]
14. Phase II study of intensified rituximab induction and maintenance for low grade B cell lymphoma.
Nagai H; Shimomura T; Takeuchi M; Hanada S; Komeno T; Sunami K; Hidaka M; Yano T; Kitano K; Yoshida I; Inoue N; Saito A; Horibe K; Motitani S; Ichihara S; Watanabe T; Sawamura M
Leuk Lymphoma; 2017 Dec; 58(12):2845-2851. PubMed ID: 28509595
[TBL] [Abstract][Full Text] [Related]
15. Rituximab plus ABVD in newly diagnosed nodular lymphocyte-predominant Hodgkin lymphoma.
Cencini E; Fabbri A; Bocchia M
Br J Haematol; 2017 Mar; 176(5):831-833. PubMed ID: 26913966
[No Abstract] [Full Text] [Related]
16. Novel Insights into Membrane Targeting of B Cell Lymphoma.
de Winde CM; Elfrink S; van Spriel AB
Trends Cancer; 2017 Jun; 3(6):442-453. PubMed ID: 28718418
[TBL] [Abstract][Full Text] [Related]
17. A review of rituximab, the first anti-CD20 monoclonal antibody used in the treatment of B non-Hodgkin's lymphomas.
Feugier P
Future Oncol; 2015; 11(9):1327-42. PubMed ID: 25952779
[TBL] [Abstract][Full Text] [Related]
18. In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis.
Salinas-Jazmín N; González-González E; Vásquez-Bochm LX; Pérez-Tapia SM; Velasco-Velázquez MA
J Vis Exp; 2017 May; (123):. PubMed ID: 28518088
[TBL] [Abstract][Full Text] [Related]
19. T-Cell-Rich Recurrence of Primary Cutaneous Follicle Center Lymphoma After Systemic Rituximab: A Diagnostic Pitfall.
Santonja C; Prieto-Torres L; Pérez-Sáenz MLÁ; Requena L; Rodríguez-Pinilla SM
Am J Dermatopathol; 2020 Mar; 42(3):e36-e40. PubMed ID: 31592859
[TBL] [Abstract][Full Text] [Related]
20. Physician Experience and Risk of Rituximab Discontinuation in Older Adults With Non-Hodgkin's Lymphoma.
Huntington SF; Hoag JR; Wang R; Zeidan AM; Giri S; Gore SD; Ma X; Gross CP; Davidoff AJ
J Natl Compr Canc Netw; 2019 Oct; 17(10):1194-1202. PubMed ID: 31590152
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
